In March 2009, Swiss pharmaceutical giant Roche agreed to pay US$46.8 billlion in cash to buy the 44 percent of California-based biotech pioneer Genentech that it didn’t already own. The deal valued the whole of Genentech at more than US$100 billion. Don’t forget to apply the USD/AUD exchange rate and consider inflation for the past 12 years…
Leslie already likening Imugene to a “mini Genentech” speaks volumes about the potential she sees.
DYOR, GLTAH
Media Thread, page-4336
-
- There are more pages in this discussion • 11,022 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
6.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $455.6M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.8¢ | 10166 | 1 |
View Market Depth
| Last trade - 09.50am 04/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
Day chart unavailable